V Clinbio Labs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 03-07-2024
- Paid Up Capital ₹ 0.10 M
as on 03-07-2024
- Company Age 11 Year, 3 Months
- Last Filing with ROC 31 Mar 2021
- Revenue %
(FY 2021)
- Profit 54.73%
(FY 2021)
- Ebitda 59.81%
(FY 2021)
- Net Worth -13.22%
(FY 2021)
- Total Assets 0.13%
(FY 2021)
About V Clinbio Labs
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Apparsundaram Kandaswamy, Apparsundram Rajanikanth, and Subramaniam Apparsundaram serve as directors at the Company.
- CIN/LLPIN
U73100TN2013PTC092866
- Company No.
092866
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Sep 2013
- Date of AGM
24 Sep 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at V Clinbio Labs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subramaniam Apparsundaram  | Managing Director | 05-Sep-2013 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Apparsundaram Kandaswamy  | Director | 05-Sep-2013 | Current |
| Apparsundram Rajanikanth | Director | 05-Sep-2013 | Current |
Financial Performance and Corporate Structure Insights of V Clinbio Labs.
V Clinbio Labs Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 54.73% increase in profit. The company's net worth observed a substantial decline by a decrease of 13.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of V Clinbio Labs?
In 2020, V Clinbio Labs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Remedium Therapeutics Private LimitedActive 4 years 4 monthsApparsundram Rajanikanth is a mutual person
Cellix Bio Pharma Private LimitedActive 4 years 10 monthsSubramaniam Apparsundaram is a mutual person
Vclinbio Pharmaceuticals Private LimitedActive 7 years 10 monthsApparsundaram Kandaswamy and Apparsundram Rajanikanth are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at V Clinbio Labs?
V Clinbio Labs has a workforce of 1 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of V Clinbio Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped V Clinbio Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
